Goldman Sachs Group Inc. Sells 67,877 Shares of Voyager Therapeutics, Inc. $VYGR

Goldman Sachs Group Inc. reduced its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 23.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 223,375 shares of the company’s stock after selling 67,877 shares during the quarter. Goldman Sachs Group Inc. owned about 0.40% of Voyager Therapeutics worth $755,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in VYGR. Strs Ohio bought a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $256,000. Acadian Asset Management LLC grew its holdings in Voyager Therapeutics by 863.3% during the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock worth $778,000 after acquiring an additional 206,758 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Voyager Therapeutics during the 1st quarter valued at $218,000. AQR Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock valued at $1,674,000 after purchasing an additional 317,927 shares during the period. Finally, Vestal Point Capital LP boosted its position in shares of Voyager Therapeutics by 1.6% in the 1st quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock worth $4,223,000 after purchasing an additional 19,418 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on VYGR shares. Wedbush dropped their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $13.25.

Voyager Therapeutics Stock Performance

VYGR stock opened at $4.10 on Wednesday. Voyager Therapeutics, Inc. has a 52 week low of $2.64 and a 52 week high of $8.27. The company has a market capitalization of $227.43 million, a PE ratio of -2.22 and a beta of 0.90. The company’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $3.42.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. On average, analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.